Modern prostate cancer imaging in daily practice
Plenary session 3

Sunday 19 July
08:00 - 10:15

Location: Orange Area, eURO Auditorium 1
Chairs: To be confirmed
To be confirmed

Learning objectives of this session
Imaging of prostate cancer is a rapidly changing field with many new technologies being established in the last few years. Actually true paradigm shifts were observed as image guided diagnosis of prostate cancer became a standard of care at last year’s EAU meeting. However, these new clinical pathways generate also problems and fields of uncertainty such as how to put them into context with modern biomarkers, how to apply these new pathways in the community setting, and how to make clinical benefit out of modern molecular imaging? This session addresses the most pertinent problems and issue encountered with modern imaging and gives answers how those might be overcome.

08:00 - 08:15
State-of-the-art lecture Ultrasound in prostate cancer imaging: Dead or ready to get started?
To be confirmed

08:15 - 08:35
When not to biopsy? Imaging and genomics in the diagnosis of prostate cancer

08:15 - 08:25
Imaging as triage
H.U. Ahmed, London (GB)

08:25 - 08:35
What might genomics add to the decision?
To be confirmed

08:35 - 09:05
Problems with imaging in real life

08:35 - 08:45
MRI in the expert center vs. MRI in the community center
To be confirmed

08:45 - 08:55
Risk stratification of prostate cancer based on targeted biopsies
B.A. Hadaschik, Essen (DE)

08:55 - 09:05
What should you do with men you do not biopsy, or whose biopsy is negative?
A. Lamb, Oxford (GB)

09:05 - 09:30
Debate Biochemical recurrence
Moderator: N.R. Suardi, Genoa (IT)

09:05 - 09:10
Case presentation Biochemical recurrence after radical prostatectomy
To be confirmed

09:10 - 09:20
Let’s ask for imaging
B. Tombal, Brussels (BE)

09:20 - 09:30
Let’s start with early treatment
P. Nyirády, Budapest (HU)

09:30 - 10:00
Case discussion Turning bright spots into meaningful action
Moderator: N. Mottet, Saint-Étienne (FR)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 - 09:35</td>
<td>Case presentation <strong>The biochemical recurrence patient</strong></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>09:35 - 09:42</td>
<td>Systemic treatment</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>09:42 - 09:49</td>
<td>Metastasis-directed therapy with radiotherapy</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>09:49 - 09:56</td>
<td>Metastases-directed therapy with surgery</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>09:56 - 10:00</td>
<td>Summary from the EAU Prostate Cancer Guidelines Panel</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>State-of-the-art lecture <strong>A peek into the future: Artificial intelligence and prostate cancer imaging</strong></td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>